Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study

Table 3

The degree of improvement in the total Target Plaque Severity Score at each assessment timepoint during treatment.

	Dose group
	0.5% (N=8)	1.0% (N=9)	2.0% (N=8)	4.0% (N=8)	Vehicle (N=7)	P value
Day 8	4.91 (6.80)	6.94 (11.02)	23.49 (10.74)	38.11 (12.13)	8.36 (23.19)	0.0004
Day 15	8.56 (9.84)	15.28 (17.19)	20.06 (22.61)	36.33 (12.39)	20.41 (34.04)	0.0663
Day 22	15.33 (11.94)	21.88 (19.52)	29.96 (2.53)	43.48 (15.62)	21.23 (18.03)	0.0172
Day 28	23.89 (16.64)	31.25 (21.13)	31.81 (26.57)	41.99 (19.90)	24.56 (19.17)	0.4666

, compared with baseline (day1).